(Q34984142)

5 August 2017

1 reference

title

Side effects of therapy of hepatitis C and their management (English)

1 reference

5 August 2017

0 references

Michael W Fried

1

1 reference

PubMed ID

12407599

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

36

1 reference

5 August 2017

5 Suppl 1

1 reference

5 August 2017

S237-44

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

5 August 2017

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Retinopathy associated with high-dose interferon alfa-2b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Reactivation of sarcoidosis during interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

The evolution of the empirical management of fever and neutropenia in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, an

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Hepatitis C, interferon alfa, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Neuropsychological impairment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Depression, fatigue, and functional disability in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Fatigue in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Depression in Korean immigrants with hepatitis B and related liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

An open-label trial of citalopram for major depression in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

21 January 2018

Depression and dysthymia

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

RANDOMIZED CONTROLLED TRIAL OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF CHRONIC HEPATITIS C

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36810

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.36810

1 reference

5 August 2017

1 reference

PubMed ID

12407599